Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Up 7.1%

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPHGet Rating) (TSE:AUP) shot up 7.1% during trading on Wednesday . The stock traded as high as $4.98 and last traded at $4.98. 24,215 shares were traded during mid-day trading, a decline of 99% from the average session volume of 3,438,562 shares. The stock had previously closed at $4.65.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on AUPH shares. Royal Bank of Canada cut their price target on Aurinia Pharmaceuticals from $18.00 to $10.00 and set an “outperform” rating for the company in a research note on Friday, November 4th. StockNews.com started coverage on Aurinia Pharmaceuticals in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Oppenheimer downgraded Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, November 4th. HC Wainwright cut their price target on Aurinia Pharmaceuticals from $26.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, November 7th. Finally, SVB Leerink cut their price target on Aurinia Pharmaceuticals from $17.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, November 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $12.25.

Aurinia Pharmaceuticals Stock Performance

The stock has a 50-day moving average price of $6.71 and a two-hundred day moving average price of $8.73.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Tcwp LLC purchased a new position in Aurinia Pharmaceuticals in the 1st quarter worth approximately $25,000. Total Clarity Wealth Management Inc. purchased a new position in Aurinia Pharmaceuticals in the 2nd quarter worth approximately $26,000. Nisa Investment Advisors LLC purchased a new position in Aurinia Pharmaceuticals in the 2nd quarter worth approximately $34,000. Geneos Wealth Management Inc. lifted its holdings in Aurinia Pharmaceuticals by 54.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 1,142 shares in the last quarter. Finally, Great West Life Assurance Co. Can purchased a new position in Aurinia Pharmaceuticals in the 3rd quarter worth approximately $49,000. 35.20% of the stock is owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Company Profile

(Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

Featured Stories

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.